EUVIMEDEUVIMED entdecken
Fallbericht

Kratom use disorder: case reports on successful treatment with home induction of buprenorphine-naloxone.

Miki Kiyokawa iD, Anthony K Kwon iD, Micaiah C Cape iD, Jon M Streltzer iD

Family Practice · 2023

DOI: 10.1093/fampra/cmad081 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Family Practice, 2023. Verfasst von Miki Kiyokawa und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, John A. Burns School of Medicine, University of Hawaii at Manoa, Honolulu, HI, United States. Hauptthemen laut MEDLINE: Mitragyna, Buprenorphine, Opioid-Related Disorders. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 17 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Kratom has been used for different reasons such as pain, opioid withdrawal, and relaxation. Kratom can cause dependence and overdose, and it’s classified under ‘drugs of concern’ by the US Drug Enforcement Administration. Despite these concerns, kratom is legal in most of the United States and many countries around the world with easy accessibility. Literature searches reveal recommendations to use buprenorphine (or buprenorphine-naloxone), which are medications to treat opioid use disorder, in order to treat patients with kratom use disorder; however, there are no formal guidelines available. Buprenorphine (or buprenorphine-naloxone) induction is recommended to be conducted under observation (i.e. in the clinic) in the United States, but COVID-19 has resulted in shifts toward telehealth.

Objectives

Describe case series of successful management of kratom use disorder using telehealth followed by unobserved buprenorphine-naloxone home induction and highlight implications for future management, including maintenance dosage and induction method.

Methods

We present 2 very similar kratom use disorder patients who reported taking 35 g of kratom per day who underwent unobserved buprenorphine-naloxone home induction.

Results

Both were seen via telehealth initially. They reported no adverse effects before, during, or after the unobserved home induction on buprenorphine-naloxone but stabilized on significantly different dosages.

Conclusion

Telehealth followed by unobserved buprenorphine-naloxone induction at home may be an alternative to traditional buprenorphine-naloxone induction where treatment accessibility is limited. In addition to daily doses of kratom use, other factors, such as duration of kratom use and individual psychological factors may determine the most comfortable dose of buprenorphine-naloxone.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MitragynaBuprenorphineOpioid-Related DisordersHumansUnited StatesBuprenorphine, Naloxone Drug CombinationPainAnalgesics, Opioid

Stichwörter der Autor:innen

addiction medicinebuprenorphinemitragynaprimary health caretelemedicine

Substanzen

Buprenorphine, Naloxone Drug CombinationBuprenorphineAnalgesics, Opioid

Autor:innen und Institutionen

  • Department of Medicine, John A. Burns School of Medicine, University of Hawaii at Manoa, Honolulu, HI, United States.
  • Department of Psychiatry, John A. Burns School of Medicine, University of Hawaii at Manoa, Honolulu, HI, United States.
  • Department of Family Medicine and Community Health, John A. Burns School of Medicine, University of Hawaii at Manoa, Honolulu, HI, United States.

ORCID-Profile: Miki Kiyokawa, Anthony K Kwon, Micaiah C Cape, Jon M Streltzer

Zitieren

APA

Kiyokawa, M., Kwon, A. K., Cape, M. C., & Streltzer, J. M. (2023). Kratom use disorder: case reports on successful treatment with home induction of buprenorphine-naloxone. Family Practice. https://doi.org/10.1093/fampra/cmad081

Vancouver

Kiyokawa M, Kwon AK, Cape MC, Streltzer JM. Kratom use disorder: case reports on successful treatment with home induction of buprenorphine-naloxone. Family Practice. 2023. doi:10.1093/fampra/cmad081

BibTeX
@article{Kiyokawa2023,
  author = {Kiyokawa, Miki and Kwon, Anthony K and Cape, Micaiah C and Streltzer, Jon M},
  title = {Kratom use disorder: case reports on successful treatment with home induction of buprenorphine-naloxone},
  journal = {Family Practice},
  year = {2023},
  doi = {10.1093/fampra/cmad081}
}
Kostenlos starten →